Shandong Boan Biotechnology (HKG:6955) obtained approval for a phase II clinical trial of its anti-CD25 antibody BA1106 from China's National Medical Products Administration.
The drug is being tested in combination with a PD-1 inhibitor BA1104 as first- or second-line regimen for non-small cell lung cancer, according to a Thursday filing.